MedPal AI gets FDA approval for Mounjaro heart protection
MedPal AI PLC said the FDA approved tirzepatide (Mounjaro) to cut the risk of heart attack and stroke in type 2 diabetes, expanding its GLP-1 market reach.
RNS Number: 9070S Medpal AI PLC 01 September 2026 1 September 2026MedPal AI plc("MedPal", the "Company" or the "Group")US Approval of Mounjaro for Heart Protection Dramatically Expands the GLP-1 MarketFDA approves tirzepatide to cut the risk of heart attack and stroke in type 2 diabetes, as El…